EIF5A2 and breast cancer: Another research conducted by Wang et al. indicated that lncTUG1 (taurine-upregulated gene 1) could modulate the susceptibility of BC cells to doxorubicin by regulating the expression of eIF5A2 (eukaryotic translation initiation factor 5A-2) via interacting with miR-9, indicating a novel potential pathway that could be targeted to overcome doxorubicin resistance in BC [95].